The Pancreatic Cancer Research Program at TGen under the direction of Daniel D. Von Hoff, MD and Haiyong Han, PhD, currently has a postdoctoral fellowship position available. Our program aims to develop novel targeted therapies for patients with advanced pancreatic cancer. We employ genomic and biochemical approaches such as whole genome sequencing and tissue array immunohistochemistry to identify alterations responsible for driving the progression and/or chemoresistance of pancreatic cancer. Promising alterations are further validated for drug targeting and candidate therapies are then developed and tested in cell line and animal models. By closely working with clinicians at TGen's Clinical Services, we seek to rapidly translate laboratory findings to the clinic. Promising therapies are promptly evaluated in pilot clinical trials.